University of California-San Francisco · Biomedical EngineeringVanbrocklin Nanomedicine Lab
Henry F. Vanbrocklin · San Francisco, California
Research Focus
Dr. Henry Vanbrocklin's lab focuses on creating innovative ways to improve prostate cancer treatment using nanomedicines. They are developing a special type of drug that carries a PARP inhibitor to tumors more effectively and is linked with a molecular imaging tool to track its delivery. Their approach aims to enhance the effectiveness of prostate cancer therapies while minimizing side effects, potentially changing how patients are treated in the future.
PARP inhibitorsnanomedicineprostate cancermolecular imagingPET imagingdrug deliverybiodistributiontherapeutic efficacy
Research Aims
4AIM 01Develop a novel PARP inhibitor nanomedicine with improved delivery to prostate tumors.
AIM 02Create a companion PET imaging agent to track the delivery of the nanomedicine.
AIM 03Test the therapeutic efficacy and safety of the drug combination in preclinical models and patients.
AIM 04Assess the feasibility of this new approach in clinical settings with prostate cancer patients.
Skills the Lab Values
cell cultureanimal modelsmolecular imaging techniquesradiolabeled tracer productiondrug delivery system developmenthigh-pressure liquid chromatographyimage analysisbiostatisticspatient-derived xenograftstranslational research methodologies
Output against the department
Publications564top 12% of dept.74th of 595
this lab
most publishedleast published
Citations5.3kbottom 41% of dept.353rd of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.